Monday, June 28, 2010
A Financial Times article tells us that Europeans are unlikely to want much flu vaccine this year. But companies will do well regardless, in part because they will be able to use stocks of influenza antigen (made under contract for last season) in the coming season's flu vaccines.
Posted by Meryl Nass, M.D. at 10:47 PM